Optimizing Treatment of Adhesive Small Bowel Obstruction
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Dec 22, 2023
Trial Information
Current as of July 01, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best ways to treat adhesive small bowel obstruction (aSBO), a condition where the intestines become blocked due to scar tissue from previous surgeries or injuries. The researchers want to find out if using a nasogastric tube (NGT) to relieve stomach pressure or using a special liquid called water-soluble contrast (WSC) is helpful for patients with this condition. They aim to see who benefits from these treatments, how to tell when the obstruction has cleared, and the best way to safely start feeding patients again after treatment.
To participate in this study, individuals need to be at least 18 years old and have signs of aSBO, such as nausea, abdominal pain, or a swollen belly confirmed by a CT scan. However, pregnant or breastfeeding women, those with certain serious health conditions, and individuals with other types of bowel obstructions are not eligible. The trial will include about 40 participants who will be monitored for up to 30 days, allowing researchers to gather important information about the treatment's effectiveness and safety.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Male or female ≥18 years of age.
- • 2. Documentation of aSBO as evidenced by one or more clinical features meeting the following criteria: Nausea, emesis, abdominal pain, distended abdomen CT evidence of aSBO
- Exclusion Criteria:
- • 1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
- • 2. Presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data.
- • 3. Unstable angina or recent myocardial infarction (MI)/stroke within 6 months
- • 4. Nonadhesive SBO
- • 1. Paralytic Ileus
- • 2. Incarcerated hernia
- • 3. Fecal impaction
- • 4. Intra-abdominal malignancy Early aSBO within 4 weeks of a prior abdominal operation
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported